Lipovir (Aciclovir)

Aciclovir is an antiviral agent that targets herpes simplex virus replication.

• Herpes labialis: reduces lesion duration and associated pain.
• Herpes simplex skin infections: promotes healing of cutaneous lesions.
• Recurrent herpes simplex outbreaks: helps shorten healing time during flare‑ups.

• After topical application, aciclovir is taken up by infected cells and phosphorylated by viral thymidine kinase to aciclovir monophosphate, then further converted to the active triphosphate form. Aciclovir triphosphate selectively inhibits viral DNA polymerase, causing premature chain termination and preventing viral DNA synthesis, thereby limiting viral replication in the treated area.

Local adverse reactions are the most frequently reported outcomes with topical aciclovir.

Common Side Effects

• Burning sensation: transient discomfort at the application site.
• Itching: mild pruritus may occur.
• Redness: localized erythema.
• Dryness: skin may feel dry or flaky.
• Stinging: brief sharp sensation.

Serious or Rare Side Effects

• Allergic contact dermatitis: severe skin reaction with swelling and rash.
• Severe skin irritation: extensive inflammation requiring medical attention.
• Ocular involvement: accidental eye exposure may cause irritation.
• Systemic absorption leading to renal toxicity: rare but possible with extensive use.
• Hypersensitivity reactions: anaphylaxis in extremely rare cases.

Before using Lipovir, consider the following safety measures.

• Use only on intact skin: avoid application to mucous membranes or open wounds.
• Known hypersensitivity: do not use if the patient has a documented allergy to aciclovir or similar antivirals.
• Immunocompromised patients: consult a healthcare professional prior to use.
• Follow prescribed amount: do not apply excessive quantities.
• Storage: Store at room temperature: keep in the original container, protect from moisture and light.

Topical aciclovir may interact with other medications applied to the same area.

Major Interactions (Avoid)

• Concurrent systemic aciclovir therapy: may increase cumulative drug exposure.
• Simultaneous use of topical ophthalmic antivirals: risk of additive irritation.

Moderate Interactions (Monitor Closely)

• Topical corticosteroids: may mask local irritation signs.
• Other topical agents (e.g., retinoids): may increase skin irritation.
• Chemotherapeutic agents affecting skin integrity: monitor for enhanced adverse effects.